Alzheimer's disease

Actinogen to present progress on Cognitive Impairment in Depression and Alzheimer's Disease Phase 2 trials at the BIO International Convention

Retrieved on: 
Wednesday, May 31, 2023
Cognition, Drug development, Depression, Cognitive deficit, Phase II, Deficit spending, Hope, ASX, EST, Attention, CMO, MADRS, ACW, Alzheimer's disease, Data analysis, MDD, Patient, Convention center, Boston Convention and Exhibition Center, Major depressive disorder, Medical device, Medical imaging, Pharmaceutical industry

SYDNEY, May 31, 2023 /PRNewswire/ -- Actinogen Medical Limited (ASX: ACW) CEO Dr Steven Gourlay and CMO Dr Dana Hilt will present at the BIO International Convention, to be held at the Boston Convention & Exhibition Center from June 5-8, 2023. The Actinogen presentation is scheduled at 4pm EST Monday June 5, in Room 403.   

Key Points: 
  • The Actinogen presentation is scheduled at 4pm EST Monday June 5, in Room 403.
  • Dr Gourlay and Dr Hilt will be discussing progress made with the Company's two ongoing Phase 2 trials:
    This Phase 2a, proof-of-concept trial commenced in December 2022 and will treat 160 patients with Major Depressive Disorder (MDD) who also have cognitive impairment.
  • Cognitive impairment is common in MDD and currently there are no anti-depressant drugs approved for its treatment, although some companies have reported trials to assess effects of their anti-depressants on cognition.
  • "Actinogen is at an important juncture in the world of drug development with its promising oral therapy Xanamem.

Brain-computer interface to control digital devices using thoughts: The European Patent Office has announced that Australian researchers have been selected as finalists for the European Inventor Award 2023

Retrieved on: 
Tuesday, May 30, 2023
Epilepsy, Surgeon, United Nations, Oxley, Locomotion, Stroke, DSM-IV codes, Quality of life, DRS, Skull, Brain, Research, Interface (computing), Movement, EPO, Paralysis, Blood, Alzheimer's disease, Motor cortex, Parkinson's disease, Patient, United, Invention, European Inventor Award, Migraine, Medical device, Medical imaging, Opie, Stent-electrode recording array, Beckman Coulter, European

In an effort to improve the quality of life for those affected, Australian researchers Drs.

Key Points: 
  • In an effort to improve the quality of life for those affected, Australian researchers Drs.
  • Thomas Oxley and Nicholas Opie invented a brain-computer interface system that transmits data from the brain wirelessly to control external digital devices hands-free, to enable patients with severe paralysis to communicate using their thoughts.
  • The research duo are finalists for the European Inventor Award in the 'Non-EPO Countries' category in recognition of their promising work.
  • The winners will be announced at a hybrid ceremony on 4 July 2023 in Valencia (Spain).

U.S. News & World Report Names Market Street Memory Care Residence Viera a Best Memory Care Community for 2 Consecutive Years

Retrieved on: 
Tuesday, May 30, 2023
Food, Research, Alzheimer's disease, Dementia, Senior living, Environment, Safety, News, Nursing, Management, U.S. News & World Report, U.S

VERO BEACH, Fla., May 30, 2023 /PRNewswire/ -- Market Street Memory Care Residence Viera celebrates the honor of being named a 2023-24 Best Memory Care Community by U.S. News & World Report.

Key Points: 
  • VERO BEACH, Fla., May 30, 2023 /PRNewswire/ -- Market Street Memory Care Residence Viera celebrates the honor of being named a 2023-24 Best Memory Care Community by U.S. News & World Report.
  • Market Street Viera is a 64-unit state-of-the-art memory care community in Melbourne, Florida, owned and operated by Watercrest Senior Living Group .
  • This is the second consecutive year Market Street Viera was prestigiously recognized by U.S. News & World Report, earning "Best" status by achieving the highest possible rating for Memory Care.
  • Market Street Memory Care Residence Viera offers world class care, multi-sensory programming, diverse culinary experiences, and unparalleled associate training honoring seniors with Alzheimer's and dementia.

FAR Biotech and Aragen Life Sciences Enter into a Collaboration to Advance Preclinical Program in Neurodegeneration

Retrieved on: 
Tuesday, May 30, 2023
FAR, Drug discovery, Biotechnology, IDD, Alzheimer's disease, Parkinson's disease, Contract research organization, Canadian industrial research and development organizations, SVP, Pharmaceutical industry

HYDERABAD, India, May 30, 2023 /PRNewswire/ -- Aragen Life Sciences (Aragen), a leading Contract Research and Development Organization (CRO), and FAR Biotech (FAR), a US-based, AI-driven, computational drug discovery company, have announced a collaboration to advance preclinical programs in neurodegeneration. As part of the collaboration, Aragen will deploy its proven experimental discovery platform to help FAR advance its small molecule program towards an important milestone in neurodegeneration.

Key Points: 
  • Aragen will provide integrated drug discovery (IDD) services to support FAR Biotech's AI-driven, quantum biomodelling approach
    HYDERABAD, India, May 30, 2023 /PRNewswire/ -- Aragen Life Sciences (Aragen), a leading Contract Research and Development Organization (CRO), and FAR Biotech (FAR), a US-based, AI-driven, computational drug discovery company, have announced a collaboration to advance preclinical programs in neurodegeneration.
  • As part of the collaboration, Aragen will deploy its proven experimental discovery platform to help FAR advance its small molecule program towards an important milestone in neurodegeneration.
  • "We look forward to initiating our collaboration with FAR Biotech to advance its pipeline of therapeutic candidates," said Dr. Ramesh Subramanian, Chief Commercial Officer, Aragen.
  • We are very pleased to be collaborating with Aragen – who we regard as a highly complementary expert partner that can help to accelerate our neurodegeneration program."

QuantalX Receives FDA Breakthrough Designation for Diagnosis of Normal Pressure Hydrocephalus and Prediction of Treatment Response

Retrieved on: 
Tuesday, May 30, 2023
CT, Vascular dementia, Prevalence, Shunt (electrical), DSM-IV codes, Stroke, Quality of life, Alzheimer's disease, Delphi, Cerebrospinal fluid, Dementia, KFAR, MRI, Science, Medtronic, Walking, VPS, Parkinson's disease, Patient, Risk, Physician, Diagnosis, Entrepreneurship, CSF, FDA, Health, NPH, Pharmaceutical industry, Medical imaging, Neuromodulation

KFAR SABA, Israel, May 30, 2023 /PRNewswire/ -- QuantalX, the developer of Delphi-MD, a novel point-of-care neurodiagnostic device, has announced that they have received the prestigious FDA breakthrough designation medical device status for another clinical application, Normal Pressure Hydrocephalus (NPH). The FDA recognized the innovative value of the device in diagnosing NPH patients and predicting the response to the recommended treatment for NPH, ventriculoperitoneal shunting (VPS) surgery.

Key Points: 
  • The FDA grants the Delphi-MD device breakthrough designation technology status for the diagnosis of Normal Pressure Hydrocephalus (NPH) patients and prediction of response to highly effective, ventriculoperitoneal shunting surgery (VPS) treatment.
  • KFAR SABA, Israel, May 30, 2023 /PRNewswire/ -- QuantalX, the developer of Delphi-MD, a novel point-of-care neurodiagnostic device, has announced that they have received the prestigious FDA breakthrough designation medical device status for another clinical application, Normal Pressure Hydrocephalus (NPH).
  • The FDA recognized the innovative value of the device in diagnosing NPH patients and predicting the response to the recommended treatment for NPH, ventriculoperitoneal shunting (VPS) surgery.
  • This marks the second time that the Delphi-MD device has been granted a breakthrough designated medical device by the FDA.

iNtRON identifies Prophage and Jamphage in the Pancreatic cancer related Microbiome

Retrieved on: 
Tuesday, May 30, 2023
SON, Survivor, Alkalihalobacillus clausii, IR, Biotechnology, Prevalence, Pancreatic cancer, Bacteriophage, Drug discovery, Survival, Open reading frame, Mode of action, Cancer, STS, Radio spectrum, Research, DSM-IV codes, Colorectal cancer, Acquisition, Parkinson's disease, Patient, Pancreas, Immune system, Intron, Mode, Growth, Bacteria, Mall of America, Recurrence, LTS, Alzheimer's disease, Genome, Vaccine, Pharmaceutical industry, Large intestine, Prophage

BOSTON and SEOUL, South Korea, May 29, 2023 /PRNewswire/ -- iNtRON Biotechnology ("iNtRON", www.intodeworld.com ) has announced today the identification of Prophage and (non-) ORF-Jamphage from the microbiome frequently observed in long-term Pancreatic cancer survivors.

Key Points: 
  • BOSTON and SEOUL, South Korea, May 29, 2023 /PRNewswire/ -- iNtRON Biotechnology ("iNtRON", www.intodeworld.com ) has announced today the identification of Prophage and (non-) ORF-Jamphage from the microbiome frequently observed in long-term Pancreatic cancer survivors.
  • The ultimate goal is to develop phage-based immunotherapeutics capable of treating a range of immune disorders including cancer.
  • The primary focus of the company lies in Colorectal cancer and Pancreatic cancer.
  • Alkalihalobacillus clausii has been identified as a representative microbiome, and iNtRON has obtained the strain and confirmed the presence of Prophage and Jamphage through the genomic analysis.

Cognition Therapeutics Latest Episode of “Conversations” Podcast Features Biomarker Experts from Gothenburg University, Emory and Amsterdam UMC

Retrieved on: 
Tuesday, May 23, 2023
Alzheimer's disease, SPARC, Pathway, Proteomics, Cognition, Research, Biomarker, Meta-analysis, Doctor of Philosophy, Patient, Effect, Therapy, Conference, Pharmaceutical industry

PURCHASE, N.Y., May 23, 2023 (GLOBE NEWSWIRE) -- Cognition Therapeutics, Inc. , (Nasdaq: CGTX), (the “Company” or “Cognition”) has released its fifth “Conversations” video podcast, a review and interactive discussion of Cognition’s CT1812 biomarker results presented at AD/PD™ 2023, the Alzheimer's & Parkinson's Diseases Conference.

Key Points: 
  • PURCHASE, N.Y., May 23, 2023 (GLOBE NEWSWIRE) -- Cognition Therapeutics, Inc. , (Nasdaq: CGTX), (the “Company” or “Cognition”) has released its fifth “Conversations” video podcast, a review and interactive discussion of Cognition’s CT1812 biomarker results presented at AD/PD™ 2023, the Alzheimer's & Parkinson's Diseases Conference.
  • This meta-analysis revealed that CT1812 treatment was associated with statistically significant changes in biomarkers associated with:
    Importantly, these changes in key biomarkers were replicated across studies, and had similar directionality and degree of change.
  • In this conversation, Dr. Charlotte Teunissen moderates a discussion on interpretation of these findings and their relevance to the CT1812 mechanism of action with two leading experts in biomarker development.
  • Episode 5 : “Exploring the Effects of CT1812 on Alzheimer’s Disease Processes: Proteomics and Pathways of Neurodegeneration” features:
    Cognition Therapeutics welcomes comments, questions and feedback on this and other Conversations episodes which may be submitted at [email protected].

Global Stem Cell Therapy Market Report 2023: Increasing Demand for Regenerative Therapies Bolsters Growth - ResearchAndMarkets.com

Retrieved on: 
Wednesday, May 24, 2023
Health, Other Health, International Marxist Group, Stem cell, Tissue, Prevalence, Tetraplegia, Cancer, Ageing, Research, USD, Regenerative medicine, Parkinson's disease, Investment, Conditional sentence, Growth, B cell, Environment, Alzheimer's disease, Pharmaceutical industry, Veterinary medicine

The "Global Stem Cell Therapy Market Report and Forecast 2023-2031" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Global Stem Cell Therapy Market Report and Forecast 2023-2031" report has been added to ResearchAndMarkets.com's offering.
  • The global stem cell therapy market value was USD 246 million in 2022, driven by the increasing demand for regenerative therapies structure across the globe.
  • The global stem cell market has experienced significant growth in recent years, driven by factors such as the rising prevalence of chronic diseases, an aging population, and the increasing demand for regenerative therapies.
  • Europe: The second-largest market, with increasing demand for stem cell therapies due to a growing awareness of their potential benefits and a supportive regulatory framework.

Global Immunoassay for Neurological Biomarkers Market Report 2023: Sector is Expected to Reach $2.24 Billion by 2030 at a CAGR of 17.8% - ResearchAndMarkets.com

Retrieved on: 
Wednesday, May 24, 2023
Biotechnology, Health, Neurology, Aducanumab, Prevalence, Serum, Roche, DSM-IV codes, Immunoassay, Research, Biomarker, Government, ELISA, PEA, Hospital, Dicarboxylic acid, Parkinson's disease, Patient, Laboratory, Investment, Blood, CSF, Growth, Diagnosis, FDA, PCR, Disease, Medical imaging, Pharmaceutical industry, Medical device, Alzheimer's disease

For instance, Fundacio Institut de Recerca de l'Hospital de la Santa Creu i Sant Pau is studying circulating microparticles to develop new biomarkers for neurological prognosis of patients.

Key Points: 
  • For instance, Fundacio Institut de Recerca de l'Hospital de la Santa Creu i Sant Pau is studying circulating microparticles to develop new biomarkers for neurological prognosis of patients.
  • Moreover, advancements in technologies help in the identification of early signs related to neurological disorders by detecting biomarkers in serum and blood.
  • Some of the multiplexed immunoassay technologies include Olink's Proximity Extension Assay (PEA) and Quanterix's Simoa.
  • The rising number of disease-modifying therapies for neurological disorders is boosting the demand for immunoassays for biomarker testing in the market.

Advanced Infusion Care (AIC) now offers Eisai infusion therapy LEQEMBI™ (Lecanemab-irmb) humanized immunoglobulin gamma 1 (IgG1) monoclonal antibody

Retrieved on: 
Tuesday, May 23, 2023
General Health, Health, Pharmaceutical, Nursing, Managed Care, Insurance, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, Accreditation Commission for Health Care, Patient, Physician, AIC, ACHC, URAC, Alzheimer's disease, Disease, Medical device, Pharmaceutical industry, Eisai

Advanced Infusion Care, a division of AIS Healthcare, now offers LEQEMBI™, developed by Eisai Co., Ltd., for the treatment of patients with Alzheimer’s disease.

Key Points: 
  • Advanced Infusion Care, a division of AIS Healthcare, now offers LEQEMBI™, developed by Eisai Co., Ltd., for the treatment of patients with Alzheimer’s disease.
  • The nationally accredited home infusion teams at AIC collaborate closely with physicians to provide specialized infusion services to patients in their home or at an infusion suite setting.
  • “We’re proud to be able to add LEQEMBI to our growing list of infusion therapies,” said Jud Hall, President at AIC.
  • “This therapy from Eisai can help us provide a new treatment option for patients with Alzheimer’s disease.”
    LEQEMBI is indicated for the treatment of Alzheimer's disease.